117 related articles for article (PubMed ID: 38319140)
1. An analysis of the prognostic role of reactive oxygen species-associated genes in breast cancer.
Zhong Y; Cao H; Li W; Deng J; Li D; Deng J
Environ Toxicol; 2024 May; 39(5):3055-3148. PubMed ID: 38319140
[TBL] [Abstract][Full Text] [Related]
2. Vasculogenic mimicry regulates immune infiltration and mutational status of the tumor microenvironment in breast cancer to influence tumor prognosis.
Zheng S; Guo G; Yang Z; Lu Y; Lu K; Fu W; Huang Q
Environ Toxicol; 2024 May; 39(5):2948-2960. PubMed ID: 38308456
[TBL] [Abstract][Full Text] [Related]
3. Development of a novel prognostic signature based on single-cell combined bulk RNA analysis in breast cancer.
Xiao Y; Hu G; Xie N; Yin L; Pan Y; Liu C; Lou S; Zhu C
J Gene Med; 2024 Feb; 26(2):e3673. PubMed ID: 38404059
[TBL] [Abstract][Full Text] [Related]
4. Unfolded protein response signature unveils novel insights into breast cancer prognosis and tumor microenvironment.
Zhou N; Kong D; Lin Q; Yang X; Zhou D; Lou L; Huang F
Cancer Genet; 2023 Aug; 276-277():17-29. PubMed ID: 37343507
[TBL] [Abstract][Full Text] [Related]
5. Identification of prognostic biomarkers for cervical cancer based on programmed cell death-related genes and assessment of their immune profile and response to drug therapy.
Feng S; Wang Z; Zhang H; Hou B; Xu Y; Hao S; Lu Y
J Gene Med; 2024 Jan; 26(1):e3643. PubMed ID: 38044747
[TBL] [Abstract][Full Text] [Related]
6. Establishment and validation of an aging-related risk signature associated with prognosis and tumor immune microenvironment in breast cancer.
Wang Z; Liu H; Gong Y; Cheng Y
Eur J Med Res; 2022 Dec; 27(1):317. PubMed ID: 36581948
[TBL] [Abstract][Full Text] [Related]
7. Oncogenic signaling pathway-related long non-coding RNAs for predicting prognosis and immunotherapy response in breast cancer.
Li H; Liu H; Hao Q; Liu X; Yao Y; Cao M
Front Immunol; 2022; 13():891175. PubMed ID: 35990668
[TBL] [Abstract][Full Text] [Related]
8. Identification of cuproptosis-related subtypes, construction of a prognosis model, and tumor microenvironment landscape in gastric cancer.
Wang J; Qin D; Tao Z; Wang B; Xie Y; Wang Y; Li B; Cao J; Qiao X; Zhong S; Hu X
Front Immunol; 2022; 13():1056932. PubMed ID: 36479114
[TBL] [Abstract][Full Text] [Related]
9. A novel hypoxia- and lactate metabolism-related signature to predict prognosis and immunotherapy responses for breast cancer by integrating machine learning and bioinformatic analyses.
Li J; Qiao H; Wu F; Sun S; Feng C; Li C; Yan W; Lv W; Wu H; Liu M; Chen X; Liu X; Wang W; Cai Y; Zhang Y; Zhou Z; Zhang Y; Zhang S
Front Immunol; 2022; 13():998140. PubMed ID: 36275774
[TBL] [Abstract][Full Text] [Related]
10. Construction of a novel choline metabolism-related signature to predict prognosis, immune landscape, and chemotherapy response in colon adenocarcinoma.
Liu C; Liu D; Wang F; Liu Y; Xie J; Xie J; Xie Y
Front Immunol; 2022; 13():1038927. PubMed ID: 36451813
[TBL] [Abstract][Full Text] [Related]
11. Identification and validation of a dysregulated TME-related gene signature for predicting prognosis, and immunological properties in bladder cancer.
Shen C; Chai W; Han J; Zhang Z; Liu X; Yang S; Wang Y; Wang D; Wan F; Fan Z; Hu H
Front Immunol; 2023; 14():1213947. PubMed ID: 37965307
[TBL] [Abstract][Full Text] [Related]
12. An Intratumor Heterogeneity-Related Signature for Predicting Prognosis, Immune Landscape, and Chemotherapy Response in Colon Adenocarcinoma.
Liu C; Liu D; Wang F; Xie J; Liu Y; Wang H; Rong J; Xie J; Wang J; Zeng R; Zhou F; Xie Y
Front Med (Lausanne); 2022; 9():925661. PubMed ID: 35872794
[TBL] [Abstract][Full Text] [Related]
13. A tumor microenvironment-related risk model for predicting the prognosis and tumor immunity of breast cancer patients.
Geng S; Fu Y; Fu S; Wu K
Front Immunol; 2022; 13():927565. PubMed ID: 36059555
[TBL] [Abstract][Full Text] [Related]
14. Identification and characterization of aging/senescence-induced genes in osteosarcoma and predicting clinical prognosis.
Lv Y; Wu L; Jian H; Zhang C; Lou Y; Kang Y; Hou M; Li Z; Li X; Sun B; Zhou H
Front Immunol; 2022; 13():997765. PubMed ID: 36275664
[TBL] [Abstract][Full Text] [Related]
15. PIK3CA mutation-driven immune signature as a prognostic marker for evaluating the tumor immune microenvironment and therapeutic response in breast cancer.
Ren X; Cui H; Dai L; Chang L; Liu D; Yan W; Zhao X; Kang H; Ma X
J Cancer Res Clin Oncol; 2024 Mar; 150(3):119. PubMed ID: 38466449
[TBL] [Abstract][Full Text] [Related]
16. Identification of a pyroptosis-related prognostic signature in breast cancer.
Chen H; Luo H; Wang J; Li J; Jiang Y
BMC Cancer; 2022 Apr; 22(1):429. PubMed ID: 35443644
[TBL] [Abstract][Full Text] [Related]
17. A novel immune-related prognostic index for predicting breast cancer overall survival.
Yu X; Guo J; Zhou Q; Huang W; Xu C; Long X
Breast Cancer; 2021 Mar; 28(2):434-447. PubMed ID: 33146847
[TBL] [Abstract][Full Text] [Related]
18. Prognostic and immune microenvironment analysis of cuproptosis-related LncRNAs in breast cancer.
Pan Y; Zhang Q; Zhang H; Kong F
Funct Integr Genomics; 2023 Jan; 23(1):38. PubMed ID: 36640225
[TBL] [Abstract][Full Text] [Related]
19. A pyroptosis-related gene signature predicting survival and tumor immune microenvironment in breast cancer and validation.
Gong M; Liu X; Zhao X; Wang H
BMC Cancer; 2022 Sep; 22(1):1005. PubMed ID: 36138348
[TBL] [Abstract][Full Text] [Related]
20. Functional enrichment analysis of LYSET and identification of related hub gene signatures as novel biomarkers to predict prognosis and immune infiltration status of clear cell renal cell carcinoma.
Chen Y; He J; Jin T; Zhang Y; Ou Y
J Cancer Res Clin Oncol; 2023 Dec; 149(18):16905-16929. PubMed ID: 37740762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
